Print

Active Biotech commences clinical studies for 57-57 project against SLE

2004-11-02

The trials entail a dose escalation study with the aim of studying safety of ABR-215757 with increasing doses in parallel groups of healthy volunteers. The study involves a small number of healthy volunteers at the Karolinska Institute hospital in Stockholm and is scheduled for completion during the first half of 2005.
The next step in the clinical development of 57-57 will be a phase I clinical trial in which the tolerance of the substance in SLE patients will be studied.
Lund, November 2, 2004
Active Biotech AB (publ)
Sven Andréasson
President and CEO
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong research portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects involve unique substances with immunomodulatory properties (SAIK-MS) intended for the treatment of multiple sclerosis, as well as a novel concept for cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
www.activebiotech.com

pdf



Back